O Shaughnessy Asset Management LLC Has $5.40 Million Holdings in Pfizer Inc. (NYSE:PFE)

O Shaughnessy Asset Management LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 55.6% during the fourth quarter, HoldingsChannel reports. The firm owned 203,518 shares of the biopharmaceutical company’s stock after selling 254,639 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Pfizer were worth $5,399,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Norges Bank bought a new stake in Pfizer during the fourth quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Pfizer during the fourth quarter worth approximately $274,694,000. Fisher Asset Management LLC increased its holdings in Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock worth $295,760,000 after purchasing an additional 4,938,209 shares in the last quarter. Finally, Van ECK Associates Corp lifted its stake in Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after buying an additional 4,726,549 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PFE shares. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Citigroup decreased their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Bank of America reissued a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Down 3.2 %

Shares of Pfizer stock opened at $24.53 on Wednesday. The company has a market capitalization of $139.09 billion, a P/E ratio of 17.39, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The stock has a fifty day simple moving average of $26.00 and a 200 day simple moving average of $26.84. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 earnings per share. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.